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Background: Experimentally, metalloproteinases (MMPs) play a detrimental role related 
to the severity of ischemic brain lesions. Both MMPs activity and function in tissues 
reflect the balance between MMPs and tissue inhibitors of metalloproteinases (TIMPs). 
We aimed to evaluate the role of MMPs/TIMPs balance in the setting of rtPA-treated 
stroke patients.
Methods: Blood was taken before and 24-h after rtPA from 327 patients (mean 
age 68 years, median NIHSS 11) with acute ischemic stroke. Delta median values 
of each MMP/TIMP ratio [(post rtPA MMP/TIMP-baseline MMP/TIMP)/(baseline 
MMP/TIMP)] were analyzed related to symptomatic intracranial hemorrhage (sICH) 
according to NINDS criteria, relevant hemorrhagic transformation (HT) defined as 
confluent petechiae within the infarcted area or any parenchymal hemorrhage, stroke 
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introduction
Matrix metalloproteinases (MMPs) are a family of zinc-dependent 
endopeptidases that are involved in extracellular matrix (ECM) 
degradation (1). The turnover of ECM is regulated by the balance 
between MMPs and a group of endogenous proteins called tissue 
inhibitor of metalloproteinases (TIMPs) (2). Active MMPs and 
some MMP proenzymes form 1:1 complexes with TIMPs and 
the unbalance between these two families of molecules appears 
implicated in a variety of diseases (3). A list of MMPs and TIMPs 
with their putative role in acute ischemic stroke is shown in Table 
S1 in Supplementary Material.
After cerebral ischemia, the general neuronal response to 
excitotoxic injury determines the release of pro-inflammatory 
cytokines that stimulate the local production of MMPs and 
TIMPs (4). In experimental models of brain ischemia, MMPs 
and MMP/TIMP unbalance play a detrimental role related to 
blood–brain barrier (BBB) disruption leading to hemorrhagic 
transformation and edema of an ischemic brain lesion (5). 
Circulating levels of MMP9 have been proved associated with 
poor outcomes in stroke patients treated with tissue plasminogen 
activator (rtPA) (6, 7). Furthermore, recent studies suggest that 
rtPA adverse effects may be mediated through MMPs upregula-
tion and activation (2). No clinical study has hitherto considered 
selectively the effect of the balance between MMPs and their 
physiological inhibitor related to stroke outcomes after throm-
bolysis. Theoretical effects of rtPA on MMP/TIMP unbalance 
have been shown in Figure 1.
The aim of this study was to evaluate the effect of MMPs/
TIMPs ratio on outcomes of ischemic stroke in the same cohort 
of the biological markers associated with acute ischemic stroke 
(MAGIC) study. Because MMP inhibition is considered a possible 
therapeutic target for stroke patients (8), a clearer understanding 
of MMP/TIMP interplay, compared with the effect of MMPs only, 
would have important implications for acute stroke therapies.
Materials and Methods
study Population
A detailed description of the biological MAGIC study is reported 
elsewhere (6). Patients were enrolled in 14 Italian centers and 
registered in the safe implementation of thrombolysis in stroke-
international stroke thrombolysis register (SITS-ISTR), according 
to SITS-monitoring study criteria (9). The diagnosis of stroke was 
based on an expert’s clinical opinion and supported by neuroimag-
ing. The Ethical Committee of the Careggi University Hospital in 
Florence approved the study protocol, and each center obtained 
ethical approval for data collection.
Data collection
For each patient variables collected were
1.  Baseline characteristics: age (years), sex (male), onset-to-
treatment time (minutes), baseline NIHSS, blood glucose 
(mg/dl), and home medications.
2.  Risk factors and comorbidities: history of hypertension, his-
tory of diabetes, history of hyperlipidemia, history of atrial 
fibrillation, history of congestive heart failure, and history of 
recent infections or inflammations.
Stroke severity was assessed using the NIHSS, administered 
before starting, at 24 h and 7 days after thrombolysis. Stroke types 
were categorized using the pathologically validated and largely used 
Oxfordshire Community Stroke Project (OCSP) classification (10), 
which distinguishes on syndromic basis four pictures: the total 
anterior circulation syndrome (TACS), the partial anterior circula-
tion syndrome (PACS), the lacunar syndrome (LACS), and the 
posterior circulation syndrome (POCS). All patients underwent a 
CT scan at baseline to determine eligibility for treatment. In addi-
tion to the baseline CT scan before treatment, patients had a CT 
at 24 h, and at any time when clinical deterioration was observed.
subtypes (according to Oxfordshire Community Stroke Project) and 3-month death. 
The net effect of each MMP/TIMP ratio was estimated by a logistic regression model 
including major clinical determinants of outcomes
results: Adjusting for major clinical determinants, only increase in MMP9/TIMP1 and 
MMP9/TIMP2 ratios remained significantly associated with sICH (odds ratio [95% confi-
dence interval], 1.67 [1.17–2.38], p = 0.005; 1.74 [1.21–2.49], p = 0.003, respectively). 
Only relative increase in MMP9/TIMP1 ratio proved significantly associated with relevant 
HT (odds ratio [95% confidence interval], 1.74 [1.17–2.57], p = 0.006) with a trend toward 
significance for MMP9/TIMP2 ratio (p = 0.007).
Discussion: Our data add substantial clinical evidence about the role of MMPs/TIMPs 
balance in rtPA-treated stroke patients. These results may serve to generate hypotheses 
on MMPs inhibitors to be administered together with rtPA in order to counteract its 
deleterious effect.
Keywords: stroke, thrombolytic therapy, metalloproteinases, tissue inhibitor of metalloproteinases, stroke 
subtypes, hemorrhagic transformation, death
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The collection of the clinical data was blinded to the biomarkers’ 
results.
laboratory Determinations
Blood samples were taken before and 24 h after rtPA. Blood was 
collected in tubes with anticoagulants (0.109M sodium citrate 
at ratio 9:1 or 1.8 mg/ml EDTA), as well as in tubes without 
anticoagulant, before starting and 24 h after thrombolysis. Tubes 
were centrifuged at room temperature at 1500 × g for 15 min, 
and the supernatants were stored in aliquots at −80°C until 
measurement of MMPs and TIMPs. Samples were analyzed in 
a unique central laboratory. Levels of different MMPs (MMP1, 
MMP2, MMP3, MMP7, MMP8, and MMP9) and TIMPs 
(TIMP1, TIMP2, and TIMP4) were determined using Bio-Plex 
suspension array system (Bio-Rad Laboratories Inc., Hercules, 
CA, USA) and R&D Kits (R&D System, Milan, Italy) following 
FigUre 1 | impact of tissue plasminogen activator on MMP/TiMP 
unbalance at the neurovascular unit level. After acute ischemic stroke, 
rtPA may cross blood–brain barrier (BBB), enter the brain parenchyma, and 
thereby damage neurovascular unit components by promoting 
metalloproteinase (MMPs) production and activation. Indeed, unbalance 
between MMPs and their natural inhibitors (tissue inhibitors of 
metalloproteinases, TIMPs) may exacerbate BBB disruption leading to 
hemorrhagic transformation and edema of an ischemic brain lesion.
manufacturer’s instructions. The coefficient of variation of 
MMPs and TIMPs assays were 5.8 and 6.8%, respectively.
Biomarker measurement was blinded to clinical data. The rela-
tive pre- and post-thrombolysis variation of MMP/TIMP ratio 
[(post rtPA MMP/TIMP-baseline MMP/TIMP)/(baseline MMP/
TIMP)] was considered as main explanatory variable.
Outcomes
Delta median values of each MMP/TIMP ratio were analyzed 
related to
1.  Symptomatic intracranial hemorrhage (sICH) defined 
as any neurologic deterioration occurring within 24  h 
after thrombolytic treatment and judged by the treating 
physician to be secondary to a new brain hemorrhage as 
shown by a head CT (11).










Age, years, mean (SD) 68.9 (12.1) 68.6 (12.1) 72.2 (11.5) 0.142
Male, n (%) 190 (58.1) 175 (58.3) 15 (55.6) 0.779
Time OT, min,  
mean (SD)
163.5 (75.7) 164.3 (78.3) 154.8 (35.8) 0.534
NIHSS, median (IQR) 11 (7–16) 11 (7–16) 15 (9–20) 0.057
Glucose, mg/dl,  
mean (SD)
129.2 (47.9) 130.0 (48.7) 133.2 (38.8) 0.735
Hypertension, n (%) 197 (61.0) 181 (60.9) 16 (61.5) 0.952
Diabetes, n (%) 50 (15.4) 46 (15.5) 4 (14.8) 0.926
Hyperlipidemia, n (%) 81 (25.8) 74 (25.6) 7 (28.0) 0.793
Atrial fibrillation, n (%) 73 (22.7) 68 (23.1) 5 (18.5) 0.590
Congestive heart  
failure, n (%)
35 (10.9) 31 (10.5) 4 (15.4) 0.440
Aspirin 105 (32.4) 92 (31.0) 13 (48.1) 0.068
Other antiplatelets 36 (11.1) 32 (10.8) 4 (14.8) 0.522
Antihypertensives 168 (51.7) 152 (51.0) 16 (59.3) 0.411
Statins 31 (9.5) 29 (9.7) 2 (7.4) 0.701
Recent infection or 
inflammation, n (%)
43 (13.2) 41 (13.7) 2 (7.7) 0.388
sICH, symptomatic intracerebral hemorrhage.*p calculated by Mann–Whitney U test for 
NIHSS, by ANOVA for other numeric variables, by Pearson χ2 for categorical variables.
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2.  Relevant hemorrhagic transformation (HT) defined as 
hemorrhagic infarction type 2 and any type of paren-
chymal hemorrhage according to ECASS II criteria (12).
3.  Subtypes of strokes defined according OCSP classification (10).
4.  Death at 3 months.
statistical analysis
We used Pearson χ2 to test for significance while comparing 
categorical variables and ANOVA test for numeric variables. To 
analyze differences in biomarkers levels between baseline and 24 h, 
we choosed the non-parametric Mann–Whitney U test because of 
relatively large statistical variations. We considered a Bonferroni 
corrected p-value <0.007 to be statistically significant.
The net effect of the variation of each MMP/TIMP ratio on 
outcomes was then estimated by a logistic regression model, 
including as covariates age, sex, onset-to-treatment time, baseline 
blood glucose, baseline NIHSS, history of atrial fibrillation, history 
of congestive heart failure, statin use, aspirin use, antiplatelet use, 
and antihypertensive use. Since there were significant variations 
in the concentration of studied biomarkers across collaborating 
centers, in the multivariate analysis, we controlled also for center 
effect. History of inflammatory disorders or infections, occurred 
in the last 7 days, was entered as a potential modifier of MMPs or 
TIMPs variations.
We used Kruskal–Wallis test to study the bivariate association 
between delta values of MMPs or TIMPs and stroke subtypes 
(according to OCSP classification). Considering the small sample 
size of LACS and POCS subtypes in comparison with TACS, we 
used the dependent dichotomous variable, TACS vs. other syn-
dromes, in the multivariate analysis. The independent association 
of MMP/TIMP ratio and ischemic stroke subtypes was analyzed 
with binary logistic regression models adjusting for age, sex, 
onset-to-treatment time, history of recent infection/inflammation, 
history of atrial fibrillation, history of hypertension, history of 
diabetes, history of congestive heart failure, statin use, aspirin use, 
other antiplatelet use, antihypertensive use, and center effect.
results
Between 2008 and 2011, 327 (mean age, 68.9 ± 12.1 years; 58% 
males) patients were enrolled in the study. A detailed description 
of the cohort enrollment has been reported in our previous paper 
(6). The rate of SICH according to the NINDS definition was 8.2%, 
relevant HT was present in 12.2% of the cohort, and mortality was 
8.6%. The rate of TACS, the most severe ischemic stroke type, was 
27.2%. Clinical and demographic characteristics of the 327 patients 
are shown in Table 1.
Pre- and Post-Thrombolysis Variations of MMPs/
TiMPs according to Outcomes
Figure  2 shows pre- and post-thrombolysis changes of each 
MMP/TIMP ratio in patients with and without sICH, in patients 
with and without relevant HT, in patients who died and in those 
who survived, and in patients with TACS compared with PACS. 
Table  2 shows multivariate analysis adjusted for major clinical 
confounders.
At univariate analysis, only relative increase in MMP9/TIMP2 
ratio proved significantly associated with sICH, while MMP9/
TIMP1 ratio showed a trend toward significance (p =  0.004, 
p = 0.018, respectively). Similarly, only MMP9/TIMP2 ratio was 
significantly associated with relevant HT (p = 0.004).
Increase in MMP8/TIMP1 and MMP9/TIMP2 ratios proved 
significantly associated with TACS (p = 0.003, p = 0.003, respec-
tively). None of the ratios examined was significantly associated 
with death. Adjusting for clinical determinants, among all ratios 
examined, only increase in MMP9/TIMP1 and MMP9/TIMP2 
ratios remained significantly associated with sICH (p =  0.005, 
p = 0.003, respectively), whereas only relative increase in MMP9/
TIMP1 ratio was significantly associated with relevant HT 
(p = 0.006) with a trend toward significance for MMP9/TIMP2 
ratio (p =  0.007). A dose–response relationship was observed 
between the incidence of symptomatic intracranial hemorrhage 
and MMP9/TIMP1 ratio quartiles (4.9% of SICH in the first 
quartile; 6.1% in the second quartile, 7.4% in the third quartile, 
14.6% in the fourth quartile, p = 0.025) and MMP9/TIMP2 ratio 
quartiles (4.9% of SICH in the first quartile; 3.7% in the second 
quartile, 8.5% in the third quartile, 15.9% in the fourth quartile, 
p = 0.006).
Discussion
The primary observation of this study is that relative increase 
of MMP9/TIMP1 and MMP9/TIMP2 ratios was independently 
associated with sICH. In a previous study (6), we have already dem-
onstrated that relative pre–post rtPA variation of just MMP-9 was 
associated with sICH. To examine whether, consistently with the 
biological rational, the effect of MMP9/TIMP 1–2 unbalance was 
stronger than MMP9 alone in determining sICH, we performed 
a stepwise regression analysis: only MMP9/TIMP1–2 ratios were 









































FigUre 2 | Pre- and post-thrombolysis variations of matrix 
metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases 
(TiMPs) ratio (Δ = [24 h MMP/TiMP − baseline MMP/TiMP]/baseline 
MMP/TiMP) in subgroups of patients with different unfavorable 
outcomes. Values are shown as median and interquartile range. sICH 
indicates symptomatic intracerebral hemorrhage.
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Possible explanation
In experimental models of brain ischemia, tissue inhibitor of 
metalloproteinases has been shown to protect BBB, inhibiting 
TaBle 2 | effect of delta MMPs/TiMPs ratio on sich, relevant hT, death, and Tacs adjusting for major determinants.
MMP/TiMP sich a
Or (95% ci)







MMP9/TIMP1 1.67 (1.17–2.38) 0.005 1.74 (1.17–2.57) 0.006 1.22 (0.92–1.63) 0.171 1.15 (0.93–1.42) 0.211
MMP1/TIMP1 1.01 (0.96–1.06) 0.704 1.01 (0.96–1.07) 0.615 0.97 (0.86–1.08) 0.554 1.02 (0.99–1.06) 0.260
MMP2/TIMP1 0.99 (0.81–1.21) 0.923 1.05 (0.86–1.29) 0.626 1.37 (1.00–1.87) 0.048 1.38 (1.06–1.80) 0.016
MMP3/TIMP1 0.85 (0.59–1.24) 0.404 0.88 (0.55–1.39) 0.579 1.00 (0.53–1.88) 0.991 1.06 (0.86–1.32) 0.587
MMP7/TIMP1 1.05 (0.97–1.13) 0.273 1.04 (0.96–1.13) 0.331 1.01 (0.92–1.11) 0.884 1.00 (0.94–1.07) 0.943
MMP8/TIMP1 0.99 (0.92–1.06) 0.788 1.00 (0.94–1.06) 0.889 1.00 (0.97–1.03) 0.730 1.01 (0.99–1.03) 0.585
MMP9/TIMP2 1.74 (1.21–2.49) 0.003 1.71 (1.16–2.52) 0.007 1.43 (1.02–1.99) 0.037 1.35 (1.03–1.78) 0.032
MMP2/TIMP2 0.99 (0.85–1.16) 0.912 1.04 (0.88–1.22) 0.652 1.27 (0.96–1.68) 0.098 1.38 (1.08–1.76) 0.009
MMP2/TIMP4 0.90 (0.68–1.19) 0.458 0.98 (0.75–1.27) 0.877 1.61 (1.10–2.36) 0.015 1.37 (1.05–1.77) 0.019
Bold font indicates statistically significant data. 
MMP, matrix metalloproteinase; TIMP, tissue inhibitors of metalloproteinase; OR, odds ratio; CI, confidence interval; sICH, symptomatic intracerebral hemorrhage; relevant HT, 
relevant hemorrhagic transformation; TACS, total anterior circulation syndrome. 
aBinary logistic regression analysis adjustment for age, sex, onset-to-treatment time, baseline blood glucose, baseline NIHSS, history of atrial fibrillation, history of congestive heart 
failure, center effect, history of recent infection/inflammation, statin use, aspirin use, antiplatelet use, and antihypertensive use. 
bBinary logistic regression analysis adjustment for age, sex, onset-to-treatment time, history of recent infection/inflammation, history of atrial fibrillation, history of hypertension, 
history of diabetes, history of congestive heart failure, statin use, aspirin use, other antiplatelet use, antihypertensive use, and center effect.
MMP9 activity. Indeed, TIMP-1 knockout mice showed MMP9 
overexpression and exacerbation of BBB leakage and ischemic 
injury (13).
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The role of MMP/TIMPs unbalance has been poorly studied 
in human stroke setting. In 41 patients evaluated for acute stroke, 
MMP9 and MMP9/TIMP1 ratios were associated with BBB 
disruption visualized in vivo by FLAIR MRI (14).
An association between MMP9/TIMP1 ratio and the most 
severe ischemic stroke subtype was found in a cohort of 126 
untreated stroke patients (15).
In a study examining human brain samples after a fatal stroke, 
MMP-9 and TIMP-2 demonstrated higher expression in brain 
microvessels, prompting the hypothesis of selectively targeting 
these molecules for “vasculoprotection” following stroke (16).
Concerning therapeutic strategies in stroke, a recent review 
of the literature discussed the current status of neuroprotection 
and extension of thrombolytic window by directly or indirectly 
inhibiting MMP-9 activity (8). These reports collectively indicate 
the importance of a balance between the levels of MMPs and their 
natural inhibitors TIMPs in maintaining the ECM integrity in 
ischemic stroke. However, the timing of inhibition is critical and 
late MMP9 inhibition may be deleterious, suggesting a role for 
MMP-9 in delayed cortical response and recovery after stroke (17).
strengths and limitations
The primary strength of this study is the relative large number of 
participants constituting the largest series hitherto investigated 
of rtPA-treated stroke patients in whom MMPs and TIMPs were 
measured before and after thrombolysis. A limitation of this study 
consists in the lack of a control group of patients not treated with 
thrombolysis. Furthermore, the use of activity assays to measure 
MMPs and TIMPs might improve the quality of future studies.
conclusion
Our data add substantial clinical evidence about the role of MMPs/
TIMPs unbalance related to hemorrhagic transformation of an 
ischemic lesion after rtPA treatment. These results may serve to 
generate hypothesis on MMPs inhibitors to be administered early, 
possibly within the same time-window of rtPA therapy, in order 
to counteract its deleterious effect.
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